SCHEMBL3784948

SCHEMBL3784948

CCC(=O)C(Cc1ccc(F)cc1Cl)C(=O)OC

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.44
POLB P06746 1/20 0.44
MAPT P10636 3/20 0.41
NR3C2 P08235 3/20 0.40
ALDH1A1 P00352 1/20 0.40
ALOX15 P16050 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TP53 P04637 1/20 0.40
KMT2A Q03164 1/20 0.40
P2RX7 Q99572 3/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CYP2D6 P10635 1/20 0.38
PKM P14618 1/20 0.38
CYP2C19 P33261 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
MDM2 Q00987 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3775566 0.86 CYP3A4 (0.47) L3MBTL1ALDH1A1ALOX15KMT2AHTT
SCHEMBL29660187 0.86 L3MBTL1 (0.48) L3MBTL1POLBMAPTNR3C2ALDH1A1
SCHEMBL3778486 0.86 ALDH1A1 (0.40) POLBMAPTALDH1A1PKM
SCHEMBL3778025 0.82 CYP3A4 (0.38) L3MBTL1MAPTALDH1A1KMT2ACYP3A4
SCHEMBL3777240 0.81 ALDH1A1 (0.40) MAPTALDH1A1ALOX15KMT2ACYP2D6
SCHEMBL533893 0.81 P2RX7 (0.41) MAPTNR3C2ALDH1A1NPSR1KMT2A
SCHEMBL1613383 0.80 L3MBTL1 (0.46) L3MBTL1POLBMAPTNR3C2ALDH1A1
Hydrochloric Acid SCHEMBL1613382 0.78 L3MBTL1 (0.45) L3MBTL1POLBMAPTNR3C2ALDH1A1
Hydrochloric Acid SCHEMBL1613380 0.78 L3MBTL1 (0.45) L3MBTL1POLBMAPTNR3C2ALDH1A1
SCHEMBL3779421 0.77 NOS2 (0.48) KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1928457-B1 QUINOLINES AND THEIR THERAPEUTIC USE PULMAGEN THERAPEUTICS ASTHMA LTD (GB) 2012-12-12 EP disclosed
US-7858640-B2 Quinolines and their therapeutic use PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2010-12-28 US disclosed
US-20090156600-A1 Quinolines and Their Therapeutic Use GB005, INC. 2009-06-18 US disclosed
EP-1928457-A2 QUINOLINES AND THEIR THERAPEUTIC USE Argenta Discovery Limited (GB) 2008-06-11 EP disclosed
WO-2007036743-A2 QUINOLINES AND THEIR THERAPEUTIC USE ARGENTA DISCOVERY LIMITED (GB) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156600-A1 Quinolines and Their Therapeutic Use NR3C1, NR3C2, NR1H3 L3MBTL1 3442/4885POLB 3247/4885MAPT 4787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.